We have previously demonstrated that sensitivity to interferon is different among hepatitis C virus (HCV) quasispecies simultaneously detected in same individuals and that interferon-resistant HCV quasispecies are selected during the treatment. To determine the genetic basis of their resistance to interferon, HCV genotype-lb was obtained from serum of three patients before and during interferon therapy, and their full-length nucleotide and deduced amino acid sequences were determined. Comparison of the pairs of interferon-resistant and interferon-sensitive HCV isolates in respective individuals demonstrated clusters of amino acid differences in the COOH-terminal half of the NS5A region (codon 2154-2383), which contained a common unique amino acid difference at codon 2218. Additional sequence data of the COOH-terminal half of the NS5A region obtained from six interferon-resistant and nine interferonsensitive HCV confirmed the exclusive existence of missense mutations in a 40 amino acid stretch of the NS5A region around codon 2218 (from codon 2209 to 2248) in interferonsensitive HCV. On the other hand, this region of interferonresistant HCV was identical to that of prototype HCV genotype-lb (HCV-J, HCV-JTa, or HC-J4). We designated this region as the interferon sensitivity determining region. Thus, HCV genotype-lb with the prototype interferon sensitivity determining region appears to be interferon-resistant strains. The specific nature of these mutations might make it possible to predict prognostic effects of interferon treatment. (J. Clin. Invest. 1995. 96:224-230.) Key words: chronic active hepatitis * interferon sensitivity determining region * polymerase chain reaction * quasispecies * single strand conformation polymorphism
Introduction
IFN is so far the sole effective therapy for chronic hepatitis C virus (HCV)' infection. However, only half of the patients treated with high doses of IFN-a (a 500 million units for 6 mo) show sustained responses to IFN with eradication of the virus (1, 2) . Especially the response rate in patients with HCV genotype-lb infection, which causes 75% of chronic HCV infection in Japan, is only 40%, whereas that of HCV genotype-2 is -80% (1, 2) . Therefore, mechanisms of IFN resistance in HCV-lb should be elucidated for achieving higher response rate of IFN therapy. Although determinants for IFN sensitivity in patients infected with HCV are not fully understood, the difference in IFN efficacy among different HCV genotypes suggests that certain differences in HCV genomes may determine the sensitivity to IFN even within the same genotypes.
HCV populations in vivo are composed of clones with various mutations throughout its genomes, so-called quasispecies (3) . In a previous study, we demonstrated by the single strand conformation polymorphism (SSCP) analysis that the sensitivity to IFN is different among HCV quasispecies simultaneously detected in same individuals, and that IEN-resistant HCV quasispecies are selected during the treatment (4) . Therefore, comparative nucleotide sequence analyses of the whole HCV genomes between IFN-resistant and IFN-sensitive HCV pairs from same individuals may reveal the specific genomic structure of IFN-resistant HCV.
In the present study, to elucidate the genetic basis of IFN resistance in HCV genotype-lb, we compared full-length nucleotide and deduced amino acid sequences of HCV genotypelb before and during IFN therapy in three patients who did not respond to IFN. To obtain the predominant HCV sequences at each time point avoiding the influence of minor sequence heterogeneity derived from the low fidelity of Thermus aquaticus (Taq) polymerase or minor HCV quasispecies, we performed the direct sequencing of the PCR products from serum HCV-RNA. Since we found common clusters of amino acid differences in the COOH-terminal half of the NS5A in these pairs, we subsequently examined this region in IFN-resistant HCV from six nonresponders and IFN-sensitive HCV from nine complete responders, and identified the IFN sensitivity determining region (ISDR) in the COOH-terminal half of the NS5A region.
Methods
Patients. 18 patients with chronic hepatitis C who underwent IFN therapy were examined. 17 patients were treated with 240-774 million units of IFN-a for 17-26 wk intramuscularly, and 1 patient was treated with 252 million units of IFN-f3 for 6 wk intravenously. Clinical characteristics and dosage schedules are summarized in Table I . Nine patients did not respond to the IFN treatment (nonresponders; patients 1-9), and nine patients showed sustained biochemical responses to LFN with the elimination of HCV for at least 6 mo (complete responders; patients 10-18). All patients had biopsy-proven chronic active hepatitis with positive serum HCV antibodies (second generation assay) and serum To obtain whole HCV genomes, PCR primers of 25-mer were designed based on the sequence of HCV-J (9) The cDNA for the extreme 3 '-end of HCV genomes was also amplified from the poly-A primed cDNA by the 3'-RACE method (10) . PCR primers for the extreme 5 '-end cDNA amplification were designed based on the nucleotide 1-12 of HC-J4/83 (11), which located upstream of the S '-end of the HCV-J sequence. For determination of the COOHterminal half of the NS5A region from patients 4-18, HCV-cDNA of nucleotide 6703-7800 was amplified as described above. PCR primers and sequencing primers were synthesized with a DNA synthesizer model 391 (Applied Biosystems Japan, Tokyo, Japan).
Direct sequencing of PCR products. 1 /l of the first PCR products of each fragment was transferred to the second PCR reaction with nested 5'-and 3'-primers. M13-forward (5'-TGTAAAACGACGGCCAGT-3') and M13-reverse (5 '-CAGGAAACAGCTATGACC-3') sequencing primer sequences were attached to the 3' terminus of 5'-and 3'-Interferon-resistant Hepatitis C Virus 225 
Results
Comparison offull-length sequences between IFN-resistant and IFN-sensitive HCV in same patients. Distribution of nucleotide differences in noncoding regions and amino acid differences in coding regions in three nonresponders (patients 1-3) are summarized in Table II . HCV genomes from patients 1-3 consisted of 9,401 nucleotides and contained an open reading frame of 3,010 amino acids. Organizations of the genomes were similar to those of HCV-J, and processing patterns of HCV polyproteins are described according to the previous reports on HCV genotype-lb (12) (13) (14) . In patient 1, 36 out of 41 amino acid differences were found in three regions of the HCV genome, the E2, the NS2, and the NS5A regions. In other regions, there were only five amino acid differences. In patient 2, amino acid differences in the structural region were exclusively found in the E2 region, and 5 out of 11 amino acid differences in the nonstructural region were detected in the NS5A region. In patient 3, although amino acid differences were more scattered, amino acid differences were most frequently found in the NS5A region among nonstructural regions (8 of 21). Table IV . No common nucleotide differences were present among three patients in the noncoding regions.
Comparison of COOH-terminal half of the NS5A in IFNtreated patients. Subsequently, amino acid sequences of the COOH-terminal half of the NS5A region were determined in additional 15 IFN-treated patients (patients 4-18) infected with HCV genotype-lb, six nonresponders (patients 4-9) and nine complete responders (patients 10-18). Amino acid sequences of IFN-resistant HCV were obtained at the end of the IFN treatment in nonresponders and those of IFN-sensitive HCV were obtained just before the treatment in complete responders. Fig. 2 demonstrates multiple amino acid sequence alignments of this region in 12 IFN-sensitive HCV and 9 IFN-resistant HCV from patients 1-18, along with three published HCV genotype-lb isolates (HCV-J, HC-J4/84 [11] , and HCV-JTa [15] ) as well as prototype HCV genotype-2a (HC-J6) (16) and genotype-2b (HC-J8) (17) . The direct sequencing from patients [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] showed no mixtures of different sequences.
The most part of this region showed a variety of differences as shown in Fig. 2 , whereas predicted amino acid sequences between codon 2209 and codon 2248 showed a distinct correlation with IFN sensitivity (IFN sensitivity determining region, ISDR). All IFN-sensitive HCV had amino acid substitutions in this region compared to HCV-J, whereas amino acid sequences of this region in prototype HCV genotype-lb (HCV-J, HCVJTa, and HC-J4) and IFN-resistant HCV were completely conserved. On the other hand, the other portions in the COOHterminal half of the NS5A region were polymorphic among HCV isolates, and showed no distinct association with IFN sensitivity. Codon insertion of 8 amino acids between codon 2221 and codon 2222. In HCV isolates from patients 15-17, amino acid residue 2218 was histidine that was same as HCV-J, while these HCV had multiple substitutions other than residue 2218. Pretreatment amino acid sequences of the ISDR in patients 4-9 were also identical to HCV-J except residue 2218 of patient 9, which was arginine and changed to histidine at the end of the treatment. The amino acid sequences of the ISDR in HCV-2a (HC-J6) and HCV-2b (HC-J8) also contained multiple amino acid substitutions as well as a deletion of four amino acids. In addition, the region from amino acid 2219 in the ISDR to the COOHterminal end of the NS5A showed very low homology between HCV-lb and HCV-2 (2a and 2b) with insertions of 4 and 20 amino acids.
Discussion
In the present study, we identified clusters of amino acid differences in the COOH-terminal half of the NS5A region between IFN-sensitive and IEN-resistant HCV genotype-lb obtained from three patients by comparative analyses of full-length nucleotide sequences of HCV genomes. All HCV pairs commonly contained an unique amino acid difference at codon 2218. Additional sequence data of the COOH-terminal half of the NS5A region obtained from six nonresponders and nine complete responders confirmed the exclusive existence of amino acid substitutions in a part of the NS5A region between codon 2209 and codon 2248 in LFN-sensitive HCV, whereas IFN-resistant HCV remained after the IFN therapy in nonresponders had an identical sequence to that of prototype HCV genotype-lb. Thus, HCV genotype-lb with the prototype sequence in this region is IFN-resistant while HCV with mutations in this region is IFN-sensitive. We designated this region ISDR.
Comparing the full-length nucleotide and deduced amino acid sequences of HCV genomes before and during IFN treatment, we found that amino acid substitutions were almost confined in the E2 region, the NS2 region, and the NS5A regions in patient 1 Further sequencing studies with 15 IFN-treated patients revealed that there was an apparent relationship between IFN sensitivity and the amino acid sequence around codon 2218 (amino acid 2209-2248, ISDR) in the NS5A region. Amino acid substitutions in the ISDR were exclusively found in the pretreatment HCV from nine IFN responders, whereas six nonresponders had HCV with prototype ISDR (identical to HCV-J) at the end of the large dose of IFN treatment. Thus, we conclude that HCV genotype-lb with the prototype ISDR is an IFN-resistant strain and HCV genotype-lb with mutant ISDR is IFN-sensitive. An amino acid residue at codon 2218 seemed to have a critical effect on IFN sensitivity. All IFNresistant HCV from patients 1-9 had histidine at this site while six of nine IFN-sensitive HCV had an amino acid other than histidine. Although three IFN-sensitive HCV (patients [15] [16] [17] had histidine in this position, they contained other substitutions in the ISDR. IFN-sensitive HCV from patient 18 had an unique insertion of eight amino acids just next to codon 2218. These results suggest that codon 2218 is most important, while the secondary structure of the entire ISDR would influence the sensitivity to ITN.
Although amino acid substitutions in the ISDR was most closely associated with IFN effect, there were several amino acid residues other than the ISDR in the COOH-terminal half of NS5A which seemed to be partially correlated to the IFN responsiveness (Fig. 2) . For example, specific amino acid residues at amino acid 2171 (arginine), 2187 (valine), and 2413 (glycine) were mainly observed in the IFN-sensitive HCV, -while they were also observed in IFN-resistant HCV. These observations suggest that the region around the ISDR may also The COOH-terminal half of the NS5A including the ISDR (amino acid 2219-2419) has been known to show marked diversity among different genotypes (la, lb, 2a, 2b, and 3a) (24) . Especially, HCV genotype-2 had a deletion of four amino acids and multiple amino acid substitutions in the ISDR, as well as numerous amino acid substitutions including insertions of 4 and 20 amino acids at the COOH-terminal end of the NS5A (Fig. 2) . The association between NS5A structure and IFN sensitivity in HCV-lb observed in the present study suggests that different IFN sensitivity among different genotypes might also be derived from the differences in the NS5A. The same approach described in this study would elucidate the existence and structure of IFN-resistant HCV in other genotypes.
Precise functions of each nonstructural protein as well as the NS5A region are not fully elucidated yet. The requirement of the NS5A region for the efficient processing of NS4 proteins by NS3 protease is suggested (14) , but it has not been confirmed. Elucidation of the function of the NS5A region and the effect of its heterogeneity on the function is needed for better understanding of IFN resistance and for the development of effective treatments. Interestingly, published HCV genotypelb isolates (HCV-J, HC-J4, and HCV-JTa) have prototype ISDR. Since each isolate was directly cloned from a single patient without PCR amplification, these patients are supposed to have relatively high serum levels of HCV-RNA. Recent investigations have shown that high titers of HCV are associated with the resistance to IFN among the same genotypes (25, 26) , implying that these prototype HCV might be IFN resistant with prototype ISDR. These findings suggest that the NS5A region might influence the rate of HCV replication. The relationship between ISDR structures and HCV replication remains to be further investigated.
In conclusion, we have identified the IFN sensitivity determining region in the NS5A region by comparing full-length sequences of IFN-sensitive and IFN-resistant HCV genotypelb in the same patients. HCV genotype-lb with prototype-ISDR shows resistance to IFN, whereas missense mutations in this region are associated with increased sensitivity to IFN. The specific nature of these mutations might make it possible to predict prognostic effects of IFN treatment.
